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tics. Results: 1534 eligible RA patients were assessed; Mono: 428 (28%), Combo: 
1106 (72%). Patient characteristics (Mono/Combo) included: age 51.8/51.7; female 
71%/75%; weight 68.6/68.5kg; top three comorbidities: dyslipidemia (16%/19%), depres-
sion/anxiety (9%/13%), obesity (8%/12%). Time since diagnosis: 68.6/78.2mo. Current 
line of biologic therapy: first-line 86%/75%, second-line 11%/18%, ≥ third-line 3%/6%. 
Top four biologics used across the two patient groups: etanercept (33%)/adalimumab 
(30%)/tocilizumab (9%)/certolizumab pegol (7%). Current lab values/disease severity 
measures: ESR (mm/h) 21.7/23.2; CRP (mg/l) 10.3/10.3; rheumatoid factor (positive) 
84%/87%; anti-CCP (positive) 70%/80%; current disease stage per physician judg-
ment: mild 65%/52%, moderate 32%/40%, severe 3%/8%; mean VAS 3.4/3.6; mean HAQ 
1.4/1.1; mean DAS 28 3.6/3.3; mean tender joint count 3.5/4.1; mean swollen joint 
count 2.4/2.6. ConClusions: In this cohort of RA patients in Europe, the majority 
of patients on monotherapy and combination therapy had mild disease per physi-
cian judgment and were on first-line biologic therapy. Lab measures and joint counts 
indicated only slightly higher disease burden among combination therapy patients. 
The impact of specific biologic treatments on observed patterns and the need for 
therapeutic sequencing may warrant further research.
PMS88
CoPing With A neW BiologiC PArAdigM: PAyer StrAtegieS for the 
PurChASing of CoMPlex BioSiMilArS
Ziai Buetas A., Vidal Pinheiro A., Storer M.
ICON, London, UK
objeCtives: In Europe, biosimilars of complex molecules such as monoclonal 
antibodies have started to enter the market. In this research we aim to provide an 
understanding of the current expectations for the purchasing of these products 
as well as an overview of the tools that payers expect to employ to encourage bio-
similar use. Methods: Qualitative survey of payers across national, regional and 
local levels in France, Germany, Italy, Spain, the UK and Netherlands. Collection and 
analysis of data on (1) current and future attitudes relative to expected biosimilar 
purchasing systems; and (2) the tools that payers expect to use to drive biosimilar 
use, assuming this is a payer goal. Results: (1) The method of biosimilar purchase 
in the short term will vary by country, with the majority of countries using tenders 
to procure these products; (2) While tenders restricting choice of product to a single 
winner will not be used extensively in the short term, these will be common across 
most countries in the future; (3) Payers will also use a number of other tools such 
as formal and informal recommendations, prescription incentives and auditing or 
prescription targets in order to encourage use of the product they have chosen; (4) 
New procurement pathways and tools are being developed to introduce biosimilars, 
as highlighted by the new biosimilar law in Italy which defines a level of discount 
at the national level. ConClusions: Payer strategies should maximize savings by 
introducing less expensive biosimilars, but also must consider physician prefer-
ences, especially when influenced by potentially valid concerns about lack of data. 
In order to do this, payers are creating novel purchasing frameworks and tools, and 
while they are currently reticent to use restrictive methods to encourage use of 
biosimilars, this is expected to rapidly change in a short timeframe.
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objeCtives: Despite Ontario’s universal health care system, differences exist 
in health care accessibility and quality across the province. The objective of this 
study is to assess health care resource utilization for patients with ankle sprains 
based on rurality. Methods: Data on individuals who sought medical attention 
for ankle sprains between 2003 and 2011 in Ontario were obtained from multiple 
databases linked through the Institute for Clinical Evaluative Sciences (ICES). The 
Rurality Index of Ontario (RIO) was used to measure the rurality level of patients 
based on their population density and geographic distance to health care facili-
ties. Demographic characteristics were obtained for each of five RIO categories. 
Health care utilization (number of visits to primary care physicians, specialists and 
ambulatory care) and physician billing costs were obtained and compared among 
the RIO categories. Results: Between 2003 and 2011, the Ontario Health Insurance 
Program was billed $64 million and $36 million (2013 CAD) by specialists and gen-
eral practitioners, respectively, for the treatment of ankle sprains and dislocations. 
Approximately $116 million was spent on direct and indirect costs of emergency 
room visits for ankle sprains and dislocations. The largest proportion of rural inju-
ries occurred in the top income quintile. Patients in the most rural RIO category 
saw specialists least often and had the highest number of ambulatory care visits. 
However, specialist visits constituted higher costs when compared to GP visits. The 
highest specialist costs found were for males, elderly patients, and those who sought 
medical attention during winter. The observed statistical differences in cost of GP 
visits across RIO categories were not clinically meaningful. ConClusions: The 
differences in health care utilization between RIO categories may indicate a lack 
of access to specialist care with those residing in rural areas relying on emergency 
departments for care. These results may be useful in allocating future resources to 
better serve rural patients.
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with CZP in workplace and household productivity, and social participation were 
sustained up to 96 wks in PsA patients.
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objeCtives: With rising pressures on health care budgets, health technology 
assessment (HTA) agencies are increasingly scrutinizing medical devices (MDs) for 
economic benefits in addition to clinical benefits. This level of scrutiny has resulted 
in many unfavorable recommendations from agencies and only a small proportion 
of unconditionally favorable reviews. As an extension of our work reported at 2013 
ISPOR Annual Congress (Dublin, IR) this study aims to: 1) Identify key criteria cited 
by HTA agencies as major decision drivers, 2) Note common criteria among reviews 
that were positive, negative, or positive with reservations, and 3) Analyze tempo-
ral or geographic trends among decision drivers. Methods: A review of 68 HTAs 
and reimbursement decisions of implantable MD with a variety of indications was 
conducted, focusing on decisions published from 2008-2013 identified by Quintiles’ 
HTA Watch from North America, Europe, and Australia. Clinical, economic, and other 
factors noted as pivotal to HTA and reimbursement decisions were registered and 
compared. Importantly, care was exercised to note only the criteria that triggered 
a HTA to make a favorable or unfavorable decision, as opposed to criteria that were 
only correlative. Results: Key product attributes affecting HTA decisions include 
1) sufficiency and quality of evidence, 2) cost offsets and budget impact, 3) adverse 
event profiles, and 4) comparison to existing alternatives where available. Notab 
ly, 33% of HTA decisions were negative, with many decisions citing insufficient 
evidence. Additionally, a majority of favorable HTA decisions were reserved in their 
recommendations, citing a need for additional evidence to uphold the initially 
favorable recommendation. The relative importance of economic considerations 
varied across countries. ConClusions: HTA agencies’ scrutiny of sufficiency of 
evidence, among others, may significantly impact market access of medical devices. 
As such, manufacturers need careful planning to align evidence development, pric-
ing and access plans with HTA agency, payer and pricing authority requirements.
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objeCtives: The process of bringing a biosimilar to market in Europe is quicker, 
easier and cheaper than developing a new biologic. As a class, rheumatoid arthritis 
(RA) has the greatest number of anti-TNF biosimilar molecules in development, with 
more expected to follow. This research was focussed on the key issues reported by 
payers and Key Opinion Leaders (KOLs) in France, Germany and Italy. Methods: 
Supported by secondary research our study entailed conducting one hour tele-
phone interviews with influential senior payers involved in budgetary decision 
making at the national and regional level in addition to KOLs. These structured 
interviews explored how stakeholders perceived the introduction of anti-TNFs bio-
similars. Results: Payers see anti-TNF biosimilars as an opportunity to reduce the 
biologic budget but KOLs want to treat more patients within the same budget. Payers 
in Germany and France reported a greater perception of the efficacy of biosimilars 
than their counterparts in Italy. Treatment naïve patients are considered most suit-
able for anti-TNF biosimilars while automatic substitution was not favoured by 
any respondents. Nonetheless, price played a role and some KOLs stated they may 
attempt to switch existing patients who have a low risk of acute complications with 
very close monitoring. ConClusions: Biosimilars may be perceived unequally 
across markets. Manufacturers are likely to require the use of differentiated value 
stories when presenting their biosimilar products to payers and KOLs, with the latter 
more inclined to perceive them as an opportunity to treat more patients with the 
same expenditure instead of reducing budgets. Manufacturers will likely struggle 
to encourage the switching of existing patients onto biosimilars without offering a 
significant discount. In France and Germany, anti-TNF RA biosimilars are currently 
generating demand that closely matches their increasing prevalence.
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objeCtives: To assess the clinical characteristics of patients with RA who received 
biologic monotherapy (“Mono”) or biologic-containing combination therapy (“Combo”) 
in Europe. Methods: A multi-country, multi-center medical chart review study of 
patients with RA was conducted in Q42012 among physicians in hospitals and pri-
vate practices to collect de-identified data on patients who were recently treated 
with a biologic as part of usual care in France/Germany/Italy/Spain/UK. Physicians 
were screened for duration of practice (3-30yrs) and patient volume (≥ 2 RA biologic 
patients/week) and recruited from a large panel to be geographically representative 
in each country. Eligible patient charts (≥ 5) were randomly selected from among 
the patients visiting each center/practice during the screening period. Physicians 
abstracted date of diagnosis, treatment patterns/dynamics, and symptomatology/
disease status. Mono and Combo patients were compared used descriptive statis-
